Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 14, 2024
Finance
Data spells money for a quintet of biotechs
NewAmsterdam’s CETP readout leads to week’s largest follow-on
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Sep 14, 2023
Regulation
Sept. 13 Quick Takes: Madrigal gets March PDUFA date for NASH therapy
Plus: Rocket parlays gene therapy update into $175M raise and updates from DalCor, Mironid, Crinetics, Shionogi, Hasten, Dewpoint and Orchid
BioCentury | Nov 23, 2022
Finance
After SPAC merger, NewAmsterdam gives back early gains in first trading day
Single-asset cardiovascular company believes it has cash to complete reinvigorated late-stage program
BioCentury | Jun 29, 2022
Deals
NewAmsterdam preps for launch of well-traveled CETP inhibitor via Menarini deal
Deal for European rights shows Menarini’s continued appetite for adding innovative assets
BioCentury | May 5, 2022
Data Byte
Top European venture fund-raisers in 2020-22 that remain private
Eleven therapeutics developers have raised at least $120 million since 2020
BioCentury | Jul 30, 2021
Deals
July 29 Quick Takes: Frazier, Takeda team up again, launching vaccine play HilleVax
With 133% gain, Icosavax leads trio of biotechs onto NASDAQ; plus Zerhouni, Nabel start-up ModeX and more
BioCentury | Apr 21, 2021
Finance
With upsized opportunity fund closing at €360M, Forbion readies to build on portfolio with three-pronged strategy
Forbion is carving out a strategy that’s differentiated from most biotech opportunity funds
Items per page:
1 - 10 of 163